To further explore the anti-tumor efficacy of SANG in vivo, the 22B-cFluc tumor bearing mice were treated intravenously with SANG at 10 mg/kg every other day throughout the experimental periods. This evidence concerns the gene GNAS-AS1 and neoplasm.